A Survey of PSA Screening Series of Wide Awake in Prostate Cancer Using Big Data Analytics
DOI:
https://doi.org/10.53555/hsn.v2i4.277Keywords:
Big Data Analytics,, Public awareness, Prostate cancer screening.Abstract
Big data driven approaches towards personalized health-care and this big data analytics in health sector provides stakeholders with new insights that have the potential to advance personalized care improve patient outcomes and avoid unnecessary costs. Big data methods require advanced techniques and technologies to enable their capture, storage, distribution, management, and analysis. Early detection of prostate cancer (PCa) with prostatespecific antigen (PSA) has led to a stage migration with increased detection of early stage, potentially curable disease. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so-called “normal” range. This paper will help to analyze the PSA screening for identifying Prostate Cancer and maintaining data in Big Data concepts.
Downloads
References
Screening for Prostate Cancer, U.S. Preventive Services Task Force, released May 2012.
Schneeweiss S, Learning from Big Health Care Data. N Engl J Med. 2014; 370: 2161.
Hans Lilja et al, “Prediction of Significant Prostate Cancer Diagnosed 20 to 30 Years Later with a Single Measure of Prostate-Specific Antigen at or Before Age 50,” Cancer 117 (2011): 1210-1219, doi: 10.1002/cncr.25568.
Early Detection of Prostate Cancer: AUA Guidelines, American Urological Association, approved by AUA Board of Directors April 2013.
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. New England Journal of Medicine2004;350(22):2239-2246.
Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. New England Journal of Medicine2001;344(18):1373-1377.
Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. Journal of the National Cancer Institute2012;104(2):125-132.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 gnpublication@
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.
By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in
